Trident Texofab (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Trident Texofab Limited |
|||
|
Price: ₹158.60 | ||
| 52 Week Low: ₹36.15 52 Week High: ₹165.10 |
|||
| Market Capital: 48.73 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Trident Texofab Share Price Target For 2024
- 1.1.1: Trident Texofab Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Trident Texofab Share Price Target For 2025
- 1.2.1: Trident Texofab Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Trident Texofab Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Trident Texofab Financial Performance
- 3.0.1: Is Trident Texofab A Good Buy For Long Term?
To predict the Trident Texofab's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Trident Texofab Share Price Target For 2024
The line chart displays the monthly closing prices of Trident Texofab with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Trident Texofab shares in 2024, see the table below.
Trident Texofab Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 171.76 (+8.28%) | Price Action: Chart |
| 2024 Target 2 | 168.56 (+6.27%) | Fibonacci Extension Level 23.60% |
| 2024 Target 1 | 165.1 (+4.09%) | Fibonacci Extension Level 100.00% |
| Current Price | 158.60 | Trident Texofab's share price as of 26 Dec 2024 |
| Stop Loss 1 | 155.65 (-1.87%) | Price Action: 18 Dec 2024 High |
| Stop Loss 2 | 152.6 (-3.79%) | Price Action: 17 Dec 2024 High |
| Stop Loss 3 | 149.65 (-5.65%) | Price Action: 16 Dec 2024 High |
Short-Term Technical Outlook
Current Technical Position: Trident Texofab is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹136.21 serves as the nearest technical reference point.
Historical Returns: 3-month: +237.73% | 6-month: +254.89% | 1-year: +150.59%
Trident Texofab Share Price Target For 2025
The line chart displays the monthly closing prices of Trident Texofab with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Trident Texofab shares in 2025, see the table below.
Trident Texofab Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 249.36 (+57.22%) | Price Action: Chart |
| 2025 Target 2 | 244.71 (+54.29%) | Price Action: Chart |
| 2025 Target 1 | 242.29 (+52.76%) | Fibonacci Extension Level 64.90% |
| Current Price | 158.60 | Trident Texofab's share price as of 26 Dec 2024 |
| Stop Loss 1 | 138.35 (-12.77%) | Price Action: 10 Dec 2024 High |
| Stop Loss 2 | 135.65 (-14.48%) | Price Action: 09 Dec 2024 High |
| Stop Loss 3 | 133.0 (-16.14%) | Price Action: 06 Dec 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Trident Texofab is currently trading near its 52-week high of ₹165.1, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +150.59% | 3-year: +232.15% | 5-year: +300.7%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Trident Texofab Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹158.60 | ||
| 2024 | ₹96.10 | -39.4% | ₹97.54 |
| 2025 | ₹189.57 | +97.26% | ₹192.41 |
| 2026 | ₹236.93 | +24.98% | ₹240.48 |
| 2027 | ₹291.64 | +23.09% | ₹296.79 |
| 2028 | ₹383.15 | +31.37% | ₹392.43 |
| 2029 | ₹455.67 | +18.92% | ₹493.85 |
| 2030 | ₹595.28 | +30.63% | ₹604.21 |
| 2031 | ₹592.00 | -0.55% | ₹600.88 |
| 2032 | ₹627.92 | +6.06% | ₹696.71 |
| 2033 | ₹742.14 | +18.19% | ₹798.13 |
| 2034 | ₹815.24 | +9.84% | ₹899.56 |
| 2035 | ₹1,000.98 | +22.78% | ₹1,015.99 |
| 2036 | ₹947.08 | -5.38% | ₹961.29 |
| 2037 | ₹964.20 | +1.8% | ₹995.02 |
| 2038 | ₹1,101.14 | +14.2% | ₹1,117.66 |
| 2039 | ₹1,205.70 | +9.49% | ₹1,305.26 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Trident Texofab Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 48.73 Crore | Market valuation of Trident Texofab's shares. |
| Revenue (TTM) | 96.35 Crore | Total revenue generated by Trident Texofab over the past twelve months. |
| Net Income (TTM) | +2.21 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +6.68% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +16.57% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-0.84% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
2.57 | Company's total debt divided by total shareholder equity. |
| Total Debt | 40.62 Crore | Sum of Trident Texofab's current & long-term financial obligations. |
Is Trident Texofab A Good Buy For Long Term?
Trident Texofab, a small-cap stock with a market cap of ₹48.73 crore, has a mixed financial performance. While it generated revenue of ₹96.35 crore, its net profit of ₹2.21 crore in the last 12 months is modest. Additionally, the company's debt of ₹40.62 crore is a concern. The stock's negative returns across various time frames indicate a downward trend. Considering these factors, it may not be an ideal buy for long-term investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
